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1. INTRODUCTION {#cam41831-sec-0001}
===============

With various adjuvant therapies for breast cancer, accurate estimate of outcomes is becoming increasingly important for appropriate tailored therapy. Currently, several prognostic factors have been identified, including tumor size, regional lymph node (LN) involvement, the presence of distant metastasis, age, histologic grade, the presence of lymphovascular invasion, hormone receptor, and human epidermal growth factor receptor 2 (HER2) status. Among these risk factors, tumor size along with regional LN status and the presence of distant metastasis constitute the basis of American Joint Committee on Cancer (AJCC) staging system.[1](#cam41831-bib-0001){ref-type="ref"} Despite recent emergence of new prognostic factors and gene expression profiling,[2](#cam41831-bib-0002){ref-type="ref"}, [3](#cam41831-bib-0003){ref-type="ref"}, [4](#cam41831-bib-0004){ref-type="ref"} tumor size remains a key factor in cancer biology. It is used in all guidelines for breast cancer and prognosis prediction models, such as Adjuvant! Online.[5](#cam41831-bib-0005){ref-type="ref"}

Traditionally, AJCC cancer staging manual for breast cancer determines T category with two cutoff values (2.0 and 5.0 cm) in the longest diameter. However, the prognostic value of this categorization has been questioned for triple‐negative or basal‐like subtypes while it is overrepresented in other subtypes.[6](#cam41831-bib-0006){ref-type="ref"}, [7](#cam41831-bib-0007){ref-type="ref"} A recent prospective study involving women with breast cancer has shown that prognoses of those whose tumors have favorable molecular features are similar regardless of whether their tumors are measured greater than or less than 2 cm.[8](#cam41831-bib-0008){ref-type="ref"} On the other hand, Yu et al[9](#cam41831-bib-0009){ref-type="ref"} have reported that larger tumor size (greater than 6.0 cm) with negative LNs might be a surrogate for biologically indolent disease of distant dissemination. Results of these studies combined indicate that current classification of tumor size might be too simplistic to categorize heterogeneous breast cancer, especially for larger sized tumors.

In this context, recent clinical trials for early breast cancer patients not only included T1 breast cancers, but also included T2 diseases as inclusion criteria for tumor size.[8](#cam41831-bib-0008){ref-type="ref"}, [10](#cam41831-bib-0010){ref-type="ref"} Some may think that biologic characteristics of a tumor are more relevant to breast cancer prognosis than the size of the tumor. However, current classification of tumor size in breast cancers is insufficient to predict accurate prognosis or intrinsic tumor biology. Current edition of AJCC cancer staging manual subcategorizes T1 breast cancers (tumor size measures 2 cm or less) into several subcategories to help guide treatment since its 3rd edition.[1](#cam41831-bib-0001){ref-type="ref"} Many clinical studies regarding small breast cancers are based on this subcategorization of T1 breast cancers. Those studies have given us better knowledge of small breast cancers. T2 category is currently not divided into subcategories even though it covers a wider range of tumor sizes than T1 category. Since heterogeneity of breast neoplasm is not confined to small breast cancer, subcategorization of T category for tumors larger than 2.0 cm might be needed. The objective of this study was to assess the feasibility of T2 subcategorization according to tumor size and determine the prognostic impact of such subcategorization using a large database for analysis.

2. METHODS {#cam41831-sec-0002}
==========

2.1. KBCR database {#cam41831-sec-0003}
------------------

The Korean Breast Cancer Society (KBCS) started collecting national data on patients with breast cancer since 1996. Korean Breast Cancer Registry (KBCR) is a prospectively maintained database of KBCS. Nationwide, breast surgeons in 102 teaching hospitals participate in this program. KBCR started offline in 1996. It has been converted to an online registration project since 2001. This registry included about 35% of all newly diagnosed breast cancer patients in Korea before 2001. After online conversion, registration rate has been increased to about 50%.[11](#cam41831-bib-0011){ref-type="ref"}, [12](#cam41831-bib-0012){ref-type="ref"}, [13](#cam41831-bib-0013){ref-type="ref"}, [14](#cam41831-bib-0014){ref-type="ref"} From 1996 through 2015, more than 160 000 breast cancer patients were registered to this registry. Detailed information regarding the KBCR database has been reported previously.[15](#cam41831-bib-0015){ref-type="ref"}

2.2. Patients selection and follow‐up {#cam41831-sec-0004}
-------------------------------------

A total of 53 878 pathologic T2 breast cancer patients were selected from KBCR, including 162 520 breast cancer patients as of 2015. For our analysis, we excluded 842 patients with distant metastases. Subsequently, 323 patients with malignant phyllodes tumors or lymphomas and 115 patients diagnosed before age of 18 years were also excluded. Additionally, 2168 patients who received neoadjuvant chemotherapy or hormonal therapy were excluded. Data for the remaining 50 430 patients were included for primary analysis. KBCR data do not include information about tumor recurrence because Korean Central Cancer Registry and Statistics Korea only provide mortality data. Total overall survival data were updated from Statistics Korea until December 31, 2014 (<http://kosis.kr>).[16](#cam41831-bib-0016){ref-type="ref"} Data of 1664 patients diagnosed after 2014 were excluded from this study. Additionally, data of 7695 patients diagnosed before 2001, the year of starting online registration, were excluded because the registration rate was relatively lower than that after online registration. Especially, using data before 1996 could cause possible selection bias because those data were registered by retrospective review. After exclusion, data for the remaining 41 071 patients were used for final analyses. The selection process of the study cohort is summarized in [Figure S1](#cam41831-sup-0002){ref-type="supplementary-material"}.

2.3. Tumor size {#cam41831-sec-0005}
---------------

During online data input process of KBCR, T category was one of required entries at the first page of online registration. Tumor size of breast cancer was an optional entry in the registration process and occasionally omitted. For that reason, we used T category as major inclusion criteria of this study. It was regarded as a more reliable variable than input value of tumor size. Cases without information about tumor size were included in primary analysis of baseline characteristics. They were excluded for subsequent analyses to subcategorize T2 category.

2.4. Statistical analysis {#cam41831-sec-0006}
-------------------------

Overall survival (OS) was defined as the time from the first diagnosis of primary breast cancer to death from any cause. Survival curves were estimated by the Kaplan‐Meier method. Log‐rank tests were used for comparison of survival curves. Time point survival was estimated using life table method. Cox\'s proportional hazard regression model was used to calculate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). Chi‐square test was used to determine differences in clinicopathologic features between pairs of groups. Receiver operator characteristic (ROC) curves were used to determine the optimal cutoff value of tumor size. All statistical analyses were carried out using SPSS, version 20.0 (SPSS Inc., Chicago, IL, USA). Two‐sided *P *\<* *0.05 was considered statistically significant.

3. RESULTS {#cam41831-sec-0007}
==========

3.1. Baseline characteristics of study population {#cam41831-sec-0008}
-------------------------------------------------

Of 41 071 patients analyzed, 34 528 (84.1%) had data of tumor sizes for analyses. Of these 34 528 patients, more than two‐thirds had breast tumors measuring between 2.0 and 3.0 cm. Patients who had tumors measuring between 3.0 and 5.0 cm were less than one‐third of them. More than half of these patients had no regional LN involvement. Among them, 58.4% were estrogen receptor (ER) or progesterone receptor (PR) positive while 18.0% had HER2 gene overexpression. Median follow‐up period was 65 months. Of 41 071 patients, 4504 (11.0%) died. Baseline characteristics and tumor size distributions of these patients are summarized in Table [1](#cam41831-tbl-0001){ref-type="table"}.

###### 

Baseline characteristics of patients with T2 tumors in KBCR

  Patient characteristics          Total (N = 41 071)   Tumor size ≤3.0 cm (n = 23 535)   Tumor size \>3.0 cm (n = 10 993)   *P*                    
  -------------------------------- -------------------- --------------------------------- ---------------------------------- ------- ------ ------- ---------
  Type of operation                                                                                                                                 
   BCS                             18 471               45.0%                             11 771                             50.0%   3414   31.1%   \<0.001
   Mastectomy                      22 137               53.9%                             11 531                             49.0%   7473   68.0%   
   etc.                            463                  1.1%                              233                                1.0%    106    0.9%    
  Year of operation                                                                                                                                 
   2001‐2005                       11 940               29.1%                             6606                               28.1%   3175   28.9%   \<0.001
   2006‐2010                       15 723               38.3%                             9182                               39.0%   4685   42.6%   
   2011‐2014                       13 408               32.6%                             7747                               32.9%   3133   28.5%   
  Patient age, years                                                                                                                                
   ≤50                             24 064               58.6%                             13 683                             58.1%   6591   60.0%   0.001
   \>50                            17 007               41.4%                             9852                               41.9%   4402   40.0%   
  Tumor size                                                                                                                                        
   \>2.0 and ≤2.5                  15 280               37.2%                                                                                       
   \>2.5 and ≤3.0                  8255                 20.1%                                                                                       
   \>3.0 and ≤3.5                  4996                 12.2%                                                                                       
   \>3.5 and ≤4.0                  3182                 7.7%                                                                                        
   \>4.0 and ≤4.5                  1687                 4.1%                                                                                        
   \>4.5 and ≤5.0                  1128                 2.7%                                                                                        
   Unknown                         6543                 15.9%                                                                                       
  N category                                                                                                                                        
   N0                              20 969               51.1%                             12 747                             54.2%   4682   42.6%   \<0.001
   N1                              12 980               31.6%                             7192                               30.6%   3458   31.5%   
   N2                              4479                 10.9%                             2305                               9.8%    1674   15.2%   
   N3                              2533                 6.2%                              1234                               5.2%    1156   10.5%   
   Unknown                         110                  0.3%                              57                                 0.2%    23     0.2%    
  Histologic grade                                                                                                                                  
   1                               3284                 8.0%                              2226                               9.5%    811    7.4%    \<0.001
   2                               14 262               34.7%                             9458                               40.2%   3910   35.6%   
   3                               16 068               39.1%                             9924                               42.2%   5301   48.2%   
   Unknown                         7457                 18.2%                             1927                               8.1%    971    8.8%    
  Lymphovascular invasion                                                                                                                           
   Yes                             13 392               32.6%                             8343                               35.4%   4435   40.3%   \<0.001
   No                              15 103               36.8%                             10 505                             44.6%   3779   34.4%   
   Unknown                         12 576               30.6%                             4687                               19.9%   2779   25.3%   
  ER status                                                                                                                                         
   Positive                        22 365               54.5%                             14 535                             61.8%   6388   58.1%   \<0.001
   Negative                        13 737               33.4%                             8445                               35.9%   4355   39.6%   
   Unknown                         4969                 12.1%                             555                                2.4%    250    2.3%    
  PR status                                                                                                                                         
   Positive                        19 842               48.3%                             12 930                             54.9%   5620   51.1%   \<0.001
   Negative                        16 088               39.2%                             10 049                             42.7%   5112   46.5%   
   Unknown                         5141                 12.5%                             556                                2.4%    261    2.4%    
  HER2 overexpression                                                                                                                               
   Positive                        7403                 18.0%                             4699                               20.0%   2274   20.7%   \<0.001
   Negative                        23 017               56.0%                             15 036                             63.9%   6482   59.0%   
   Unknown                         10 651               25.9%                             3800                               16.1%   2237   20.3%   
  Chemotherapy                                                                                                                                      
   Yes                             30 202               73.5%                             19 117                             81.2%   9033   82.2%   \<0.001
   No                              3787                 9.2%                              2471                               10.5%   924    8.4%    
   Unknown                         7082                 17.2%                             1944                               8.3%    1036   9.4%    
  Radiation therapy                                                                                                                                 
   Yes                             18 503               45.1%                             12 301                             52.3%   4903   44.6%   \<0.001
   No                              13 563               33.0%                             8243                               35.0%   4350   39.6%   
   Unknown                         9005                 21.9%                             2991                               12.7%   1740   15.8%   
  Endocrine therapy                                                                                                                                 
   Yes                             20 126               49.0%                             13 718                             56.0%   5706   51.9%   \<0.001
   No                              10 630               25.9%                             6613                               28.1%   3224   29.3%   
   Unknown                         10 315               25.1%                             3744                               15.9%   2063   18.8%   
  Median follow‐up, months (IQR)   65 (31‐105)          65 (32‐105)                       68 (33‐103)                                               
  Death, all causes                4504                 11.0%                             2225                               9.5%    1590   14.5%   

BCS, breast‐conserving surgery; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IQR, interquartile range; KBCR, Korean Breast Cancer Registry; PR, progesterone receptor.
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3.2. Determination of optimal cutoff value {#cam41831-sec-0009}
------------------------------------------

First, we categorized the study population into six groups according to tumor size with an interval of 0.5 cm. When survival outcomes of these six groups were compared, OS was negatively correlated with tumor size (Figure [1](#cam41831-fig-0001){ref-type="fig"}A). Between any two groups among these six T2 subgroups, OS differed from each other. To determinate an optimal cutoff of tumor size, we examined ROC curves from tumor size and patients' survival outcome. Optimal cutoff point subdividing T2 category into two subcategories was found to be 2.95 cm in this study population ([Figure S2](#cam41831-sup-0002){ref-type="supplementary-material"}). We selected 3.0 cm instead of 2.95 cm as a cutoff value because of its simplicity as a representative value.

![Survival curves for T2 breast cancer patients stratified by categorical tumor size. A, Six groups categorized by interval of 0.5 cm; B, Two T2 subcategories divided by a cutoff value of 3.0 cm (tentatively named T2a and T2b). OS, overall survival](CAM4-7-5514-g001){#cam41831-fig-0001}

3.3. Comparison of two T2 subcategories {#cam41831-sec-0010}
---------------------------------------

Of 34 528 patients analyzed, 23 535 (68.2%) had tumors with size between 2.0 and 3.0 cm (tentatively named T2a) while 10 993 (31.8%) patients had tumors with size between 3.0 and 5.0 cm (tentatively named T2b). Patient and tumor characteristics of each subcategory are presented in Table [1](#cam41831-tbl-0001){ref-type="table"}. Patients with T2b breast tumors showed more advanced node categories than patients with T2a (*P *\<* *0.001). T2b tumors also showed different features from T2a tumors in histologic grade, hormone receptor status, HER2 gene expression status, and lymphovascular invasiveness. The ratio of T2a to T2b did not change until 2010. After that, the proportion of T2a disease was increased (*P *\<* *0.001). Patients with T2b tumors showed worse OS than patients with T2a tumors (HR: 1.51; 95% CI = 1.42‐1.61; log‐rank *P *\<* *0.001; Figure [1](#cam41831-fig-0001){ref-type="fig"}B). Five‐year OS rate was 91% in T2a patients and 86% in T2b patients.

3.4. Prognostic significance of T2 subcategorization {#cam41831-sec-0011}
----------------------------------------------------

To determinate influences of different node status on the two T2 subcategories, the effect of T2 subcategorization was evaluated for each pathologic node category. Patients with T2b breast cancer showed consistently worse survival outcome than patients with T2a regardless of pathologic node categories (log‐rank *P *\<* *0.001 in all node categories; Figure [2](#cam41831-fig-0002){ref-type="fig"}). Survival differences between T2a and T2b were more pronounced in advanced node categories (N2 and N3) than those in early node category (N0 and N1). Additionally, within each T2 subcategory, prognostic values of pathologic node categories were reevaluated. Although distributions of node categories were quite different between the two T2 subcategories, pathologic node category was still a powerful prognostic factor in both subcategories. Within any T2 subcategory, the presence of positive lymph node was associated with worse prognosis (Figure [3](#cam41831-fig-0003){ref-type="fig"}). These findings suggest that the prognostic value of T2 subcategorization is independent of pathologic node categories. We then performed subgroup analyses according to breast operation type, ER status, PR status, HER2 gene expression status, histologic grade, nuclear grade, lymphovascular invasion, receipt of adjuvant therapy, and age (50 years or more vs less than 50 years). In every subgroup, T2b breast cancer patients consistently showed worse outcome than T2a breast cancer patients (Table [2](#cam41831-tbl-0002){ref-type="table"}). In univariate survival analyses, long‐term outcomes were significantly different according to pathologic node categories, ER status, PR status, HER2 gene expression status, histologic or nuclear grade, lymphovascular invasion, age (50 years or more vs less than 50 years), receipt of adjuvant therapy, and T2 subcategory. T2b subcategory (tumors \> 3 cm) was a significant independent risk factor affecting OS in a model with variables including tumor size (≤ 3 cm vs \> 3 cm), LN status (N0 vs N1 vs N2 vs N3), histologic grade (grade 1 vs 2 vs 3), lymphovascular invasion (negative vs positive), ER and PR status (negative vs positive), HER2 gene overexpression status (negative vs positive), receipt of adjuvant chemotherapy (no vs yes), receipt of adjuvant radiation therapy (no vs yes), receipt of endocrine therapy (no vs yes), age (less than 50 years vs 50 years or more), and time of operation (2001‐2005 vs 2006‐2010 vs 2011‐2014). In multivariate analyses, patients with breast cancer size larger than 3.0 cm had a HR for OS of 1.26 (95% CI = 1.18‐1.34). Advanced node categories, higher histologic grade, ER negativity, PR negativity, omission of any adjuvant therapy, older age (50 years or more), and past year of operation were also independent risk factors in multivariate analyses (Table [3](#cam41831-tbl-0003){ref-type="table"}).

![Survival comparison between two T2 subcategories within each node category. A, N0; B, N1; C, N2; and D, N3. Women with T2b breast cancers showed consistently worse outcomes in every node category than women with T2a breast cancers](CAM4-7-5514-g002){#cam41831-fig-0002}

![Survival curves for each node category within two T2 subcategories. A, T2a, 2.1‐3.0 cm and B, T2b, 3.1‐5.0 cm. Advanced node categories similarly worsened the prognosis within any T2 subcategory](CAM4-7-5514-g003){#cam41831-fig-0003}

###### 

Hazard ratios regarding overall survival by subgroup analyses according to clinicopathologic risk factors

![](CAM4-7-5514-g004){#nlm-graphic-9}
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###### 

Univariate and multivariate analyses regarding overall survival

  Variable                      Univariate analysis   Multivariate analysis[\[Link\]](#cam41831-note-0004){ref-type="fn"}               
  ----------------------------- --------------------- --------------------------------------------------------------------- ----------- -----------
  Tumor size                                                                                                                            
   T2a (\>2.0 cm and ≤3.0 cm)   Reference                                                                                   Reference   
   T2b (\>3.0 cm and ≤5.0 cm)   1.51                  1.42‐1.61                                                             1.26        1.18‐1.34
  N category                                                                                                                            
   N0                           Reference                                                                                   Reference   
   N1                           1.70                  1.58‐1.83                                                             1.70        1.56‐1.85
   N2                           2.55                  2.34‐2.79                                                             2.73        2.47‐3.03
   N3                           5.11                  4.69‐5.57                                                             5.36        4.84‐5.94
  Histologic grade                                                                                                                      
   1                            Reference                                                                                   Reference   
   2                            1.76                  1.51‐2.06                                                             1.40        1.19‐1.65
   3                            2.46                  2.12‐2.87                                                             1.69        1.43‐1.99
  Lymphovascular invasion                                                                                                               
   No                           Reference                                                                                   Reference   
   Yes                          1.83                  1.70‐1.96                                                             1.24        1.14‐1.34
  ER status                                                                                                                             
   Negative                     Reference                                                                                   Reference   
   Positive                     0.61                  0.57‐0.65                                                             0.72        0.65‐0.79
  PR status                                                                                                                             
   Negative                     Reference                                                                                   Reference   
   Positive                     0.58                  0.55‐0.62                                                             0.76        0.69‐0.83
  HER2 overexpression                                                                                                                   
   Negative                     Reference                                                                                   Reference   
   Positive                     1.28                  1.18‐1.38                                                             0.965       0.89‐1.05
  Chemotherapy                                                                                                                          
   No                           Reference                                                                                   Reference   
   Yes                          0.75                  0.67‐0.83                                                             0.51        0.45‐0.57
  Radiation therapy                                                                                                                     
   No                           Reference                                                                                   Reference   
   Yes                          0.93                  0.87‐1.00                                                             0.75        0.69‐0.81
  Endocrine therapy                                                                                                                     
   No                           Reference                                                                                   Reference   
   Yes                          0.66                  0.62‐0.71                                                             0.95        0.87‐1.05
  Age                                                                                                                                   
   ≤50                          Reference                                                                                   Reference   
   \>50                         1.51                  1.43‐1.60                                                             1.40        1.31‐1.50
  Year of diagnosis                                                                                                                     
   2001‐2005                    Reference                                                                                   Reference   
   2006‐2010                    0.77                  0.72‐0.82                                                             0.78        0.72‐0.84
   2011‐2014                    0.61                  0.53‐0.69                                                             0.65        0.56‐0.75

CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor.

All significant risk factors for overall survival in univariate analyses except nuclear grade were incorporated into subsequent multivariate analysis using Cox\'s proportional hazard model. We excluded nuclear grade in our multivariate analysis because it was a potential confounder for histologic grade in its nature.
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4. DISCUSSION {#cam41831-sec-0012}
=============

Cancer staging is central to the modern management of cancer patients. Any good staging system must be valid, reliable, and above all, it must be practical.[17](#cam41831-bib-0017){ref-type="ref"} A practical staging system must be suitable for daily use in a wide range of clinical environments and must not require diagnostic procedures that are not readily available to most practitioners. In this context, TNM staging system which was based on anatomic extent of malignant disease has been the most practical one for most of malignant diseases. Our attempt to subcategorize T2 in breast cancer was very practical, but holds a definite prognostic value. Although biologic features of breast tumor hold an evident clinical importance other than the current anatomic staging system, we do not need to abandon its practical value. Furthermore, new knowledge supporting a change in staging system might be created by facilitating clinical studies based on the new staging system itself.

The prognostic influence of T2 subcategorization in this study was independent of node status. Studies conducted over several decades have concluded that tumor size and the number of involved LN are positively correlated.[18](#cam41831-bib-0018){ref-type="ref"}, [19](#cam41831-bib-0019){ref-type="ref"}, [20](#cam41831-bib-0020){ref-type="ref"}, [21](#cam41831-bib-0021){ref-type="ref"} As T2 breast cancer size ranges from 2.0 to 5.0 cm, axillary LN status in T2 breast cancers might be more diverse than that in T1. Given that axillary node metastasis is one of the most powerful prognostic factors in breast cancer, we should also consider axillary node status when we assess the prognostic value of T2 subcategorization. In this study, patients with T2b tumors showed consistently worse outcomes in every node category than patients with T2a tumors (Figure [2](#cam41831-fig-0002){ref-type="fig"}). Furthermore, pathologic node category was a powerful prognostic factor in both T2 subcategories, although the distribution of node categories was quite different between the two T2 subcategories (Figure [3](#cam41831-fig-0003){ref-type="fig"}). These results suggest that tumor size is an independent prognostic factor within the range of T2 category regardless of axillary node status.

In this study, more than two‐thirds of 34 528 patients analyzed were subcategorized to T2a (Table [1](#cam41831-tbl-0001){ref-type="table"}). Characteristics of T2 category might be mainly determined by T2a subcategory being confined to the range of only 1 cm wide. Because patients with T2a tumors, as stated above, clearly showed better survival outcomes than patients with T2b tumors, this uneven distribution might have hidden the poor survival outcome of T2b subcategory representing relatively smaller proportion in T2 category. It is not reasonable that characteristics of T2 category in a whole are affected by those of T2a subcategory which represents only a small part of the whole range of T2 category.

Some subtypes of breast cancer might have enhanced propensity to metastasize when they are very small. On the other hand, some large breast tumors might metastasize late, if they metastasize at all.[6](#cam41831-bib-0006){ref-type="ref"}, [22](#cam41831-bib-0022){ref-type="ref"}, [23](#cam41831-bib-0023){ref-type="ref"}, [24](#cam41831-bib-0024){ref-type="ref"} Because of such heterogeneity, current anatomic staging of breast cancer may fail to accurately capture the behavior of some tumors or patient prognosis. This limitation of anatomic staging has resulted in the incorporation of ER status, HER2 status, grade, and molecular tumor characteristics into the 8th edition revision of AJCC cancer staging for breast cancer.[25](#cam41831-bib-0025){ref-type="ref"}, [26](#cam41831-bib-0026){ref-type="ref"} Unfortunately, the survival difference between the two T2 subcategories in this study was not fully explained by the model after adjusted for those biologic risk factors (Tables [2](#cam41831-tbl-0002){ref-type="table"} and [3](#cam41831-tbl-0003){ref-type="table"}). Although the staging system starts to incorporate aspects of tumor biology, examining anatomic staging in more details might be still important.

The validity of T2 subcategorization in this study might be supported by several recent studies using SEER database. In the work of Wo et al,[27](#cam41831-bib-0027){ref-type="ref"} breast cancer‐specific mortality is positively correlated with tumor size in the range of T2 as well as T1. Although such correlation was pronounced in tumors less than 3.0 cm, it was unclear for tumors larger than 3 cm. The increase in breast cancer‐specific mortality reached a plateau despite increasing tumor size in tumors measuring 3 cm or more. Similar results have been reported in other recent studies based on SEER database.[9](#cam41831-bib-0009){ref-type="ref"}, [28](#cam41831-bib-0028){ref-type="ref"} Additionally, Lannin et al[29](#cam41831-bib-0029){ref-type="ref"} have reported that the distributions of biologic features of breast cancer categorized by ER, PR status, and histologic grade are different according to tumor size. In their study, favorable features (lower grade and hormone receptor positive) are more frequent but unfavorable features (higher grade and hormone receptor negative) are less frequent in smaller tumors. The distribution of biologic category showed marked difference according to tumor size in the range of 0.1‐3.0 cm. However, the difference was not evident when the tumor size was greater than 3.0 cm. Findings of these studies suggest that tumors larger than 3 cm might be different in their biologic features from tumors smaller than 3 cm. Thus, cutoff point of tumor size could be used to subdivide T2 category.

Our study has several limitations. First, data of adjuvant therapy were not complete in this analysis. As T2b breast cancers had relatively unfavorable biologic features, there might be differences in application of adjuvant therapy between the two groups. Within our dataset, adjuvant chemotherapy was more frequent among patients with T2b tumors, but adjuvant radiation and endocrine therapy were more common among patients with T2a tumors. These findings were not surprising considering BCS was much more frequent, and the proportion of ER‐positive disease was higher among T2a tumors than among T2b tumors. As our data of adjuvant therapy contain considerable missing values, unexpected deviation among them should be considered. However, this possible deviation might reduce survival difference taking the worse biologic features of T2b tumors into consideration. Thus, it is unlikely to introduce confounding effect pronouncing survival difference. In addition, tumor size was unknown in 15.9% of primary eligible 41 071 patients. This was inevitable because tumor size was not a required entry in KBCR, which could be omitted. However, there was no specific pattern of these omissions. Thus, they would be likely to be random. They are unlikely to change our result. Another limitation of the present study was in its study end point and relatively short follow‐up period. We defined OS as a study end point instead of disease‐specific survival (DSS) or disease recurrence (DR). OS is not ideal as an end point compared with DSS or DR. However, OS represents DSS even though it is less sensitive for the breast cancer‐specific mortality. For our purpose to define survival difference between the two T2 subcategories, OS would be used as a surrogate for DSS, because difference in OS is likely to be less prominent than that of DSS. Median follow‐up period for OS in this study was 65 months, which was short to detect late recurrences among ER‐positive breast cancers. As more than half of entire cohort with T2 tumors had ER‐positive breast cancers, further follow‐up for those population should be warranted. Finally, all patients enrolled in this study were Koreans (ethnically homogenous Far East Asian). The significance of T2 subcategorization and cutoff value in the current study might be limited to this ethnic group. However, given previous studies using SEER database, similar findings have been found in Western women.[9](#cam41831-bib-0009){ref-type="ref"}, [26](#cam41831-bib-0026){ref-type="ref"}, [27](#cam41831-bib-0027){ref-type="ref"}

In conclusion, our study revealed that T2 category in breast cancer could be subcategorized into two subcategories: tumors ≤3 cm and tumors \>3 cm. Those two subcategories clearly showed different OS after adjusting for known breast cancer prognostic factors. This result may reflect differences in biologic features between T2a and T2b. More detailed classification of tumor size might help us predict prognosis more accurately and provide tailored adjuvant therapy. The distinct prognostic difference between those T2 subcategories warrants further investigation.
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